Literature DB >> 1547834

Class-specific antibodies to bovine respiratory syncytial virus in experimentally infected lambs.

R Sharma1, Z Woldehiwet.   

Abstract

Enzyme-linked immunoabsorbent assay (ELISA) was used to titrate virus-specific IgG, IgM and IgA levels in nasal secretions, lung lavage fluids and serum samples sequentially obtained from lambs experimentally infected with bovine respiratory syncytial virus (RSV). Virus-specific IgG and IgM responses were measured by the indirect double antibody sandwich ELISA using anti-bovine RSV monoclonal antibody, as capture antibody, and peroxidase-conjugated anti-sheep IgG and anti-sheep IgM. Virus-specific IgA antibodies were measured by antibody capture assay using anti-sheep IgA (alpha-chain specific) and anti-bovine RSV monoclonal antibodies. Bovine RSV-specific IgM and IgA antibodies were detected in the serum samples within 6 days post-inoculation (p.i.). Virus-specific IgC antibodies appeared in serum samples 4 days later. In nasal secretions, IgA antibodies appeared 7 days p.i. but IgM antibodies were not detected until 12-16 days p.i. In serum samples, IgM titres were predominant for the first 2 weeks p.i. IgC titres becoming predominant thereafter. In nasal secretions and lung lavage fluids, IgA titres were significantly higher than IgM or IgG titres up to 21 days p.i. (0.01).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1547834      PMCID: PMC2272185          DOI: 10.1017/s095026880004958x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  37 in total

1.  Field trial of a quadrivalent vaccine against calf respiratory disease.

Authors:  E J Stott; L H Thomas; C J Howard; R N Gourlay
Journal:  Vet Rec       Date:  1987-10-10       Impact factor: 2.695

2.  Increased susceptibility to Pasteurella haemolytica in lambs infected with bovine respiratory syncytial virus.

Authors:  R Sharma; Z Woldehiwet
Journal:  J Comp Pathol       Date:  1990-11       Impact factor: 1.311

3.  Neutralizing and hemagglutination-inhibiting activity of nasal secretions following experimental human infection with A2 influenza virus.

Authors:  R H Alford; R D Rossen; W T Butler; J A Kasel
Journal:  J Immunol       Date:  1967-04       Impact factor: 5.422

4.  Survey for antibodies to respiratory viruses in two groups of sheep in Northern Ireland.

Authors:  B M Adair; J B McFerran; E R McKillop; S J McCullough
Journal:  Vet Rec       Date:  1984-10-20       Impact factor: 2.695

5.  Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection.

Authors:  K McIntosh; J McQuillin; P S Gardner
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

6.  Pathogenesis of experimental bovine respiratory syncytial virus infection in sheep.

Authors:  F J Trigo; R G Breeze; J F Evermann; A M Gallina
Journal:  Am J Vet Res       Date:  1984-08       Impact factor: 1.156

7.  Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections.

Authors:  M P Cranage; P S Gardner
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

8.  Isotype-specific ELISAs for the detection of antibodies to bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink; P J Straver; D Van Zaane; B E Schreuder
Journal:  Res Vet Sci       Date:  1987-09       Impact factor: 2.534

9.  Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies.

Authors:  T G Kimman; F Westenbrink; B E Schreuder; P J Straver
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

10.  Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus.

Authors:  H W Kim; J O Arrobio; G Pyles; C D Brandt; E Camargo; R M Chanock; R H Parrott
Journal:  Pediatrics       Date:  1971-11       Impact factor: 7.124

View more
  1 in total

1.  Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.

Authors:  Teun Guichelaar; Jeroen Hoeboer; Myra N Widjojoatmodjo; Sylvia S N Reemers; Cécile A C M van Els; Rob Otten; Yvonne van Remmerden; Jolande Boes; Willem Luytjes
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.